Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited (TEVA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
teva · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Teva Pharmaceutical Industries Limited (TEVA) measures how much investors pay for each dollar of the company's trailing earnings. TEVA's current PE ratio of 25.49x is calculated by dividing its stock price of $34.33 by its TTM earnings per share of $1.36. −37.3% discount vs 5Y avg 40.6x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 13 fiscal years · Front-end computedMinQ1 · 25%24.5x
MedianQ3 · 75%105.2x
Max
At 25.49x, TEVA's current P/E is within its average historical range over the past 13 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Teva Pharmaceutical Industries LimitedYou TEVA | $40.0B | 25.49x | -2.2% | $1.36 |
 Biogen Inc. BIIB | $28.7B | 19.96x | -23.4% | $8.82 |
 BioNTech SE BNTX | $22.0B | N/A | — | -$4.51 |
 DexCom, Inc. DXCM | $29.7B | 30.97x | +18.8% | $2.14 |
 Labcorp Holdings Inc. LH | $21.6B | 23.81x | -8.6% | $10.53 |
 Neurocrine Biosciences, Inc. NBIX | $16.4B | 29.49x | +13.2% | $4.81 |
 Natera, Inc. NTRA | $30.9B | N/A | — | -$1.52 |
Industry Average 4 peers with valid PE | — | 26.06x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 25.43x | $1.23 | — | |
2024-12-31 FY2024 | — | $-1.45 | — | |
2023-12-31 FY2023 | — | $-0.50 | — | |
2022-12-31 FY2022 | — | $-2.20 | — | |
2021-12-31 FY2021 | 21.17x | $0.38 | — | |
2020-12-31 FY2020 | — | $-3.64 | — | |
2019-12-31 FY2019 | — | $-0.92 | — | |
2018-12-31 FY2018 | — | $-2.11 | — | |
2017-12-31 FY2017 | — | $-16.01 | — | |
2016-12-31 FY2016 | 105.22x | $0.34 | +197.7% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Teva Pharmaceutical Industries Limited (TEVA) measures how much investors pay for each dollar of the company's trailing earnings. TEVA's current PE ratio of 25.49x is calculated by dividing its stock price of $34.33 by its TTM earnings per share of $1.36.
Frequently asked questions
TEVA pe ratio · 6 questionsTEVA's current PE ratio is 25.49x as of 2026-06-08, based on a stock price of $34.33 and TTM EPS of $1.36. Data sourced from Financial Modeling Prep via TEVA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Teva Pharmaceutical Industries Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08